secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2022-04-13T23:59:59+00:00
Accession:  0001564590-22-014285
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma gets FDA orphan drug designation for efzofitimod in systemic sclerosis
--------------------------------------------------------------------------------

- FDA granted orphan drug designation for efzofitimod to treat systemic sclerosis (scleroderma) on April 12, 2022.
- Efzofitimod is aTyr's lead therapeutic candidate; orphan status provides development incentives and market exclusivity potential.
- Systemic sclerosis is a rare autoimmune disease; designation underscores unmet medical need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000156459022014285/0001564590-22-014285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000156459022014285/life-8k_20220412.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-014285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer